Research Article | Open Access
Volume 2021 - 1 | Article ID 197 | http://dx.doi.org/10.51521/IRJCPT.2021.1208
Academic Editor: Dr. Wendy Yeo Wai Yeng
IRRIPOTHU PAULA PREETHI1, YETIGADDA VAMSI PRIYA1, SUNKARA HIMA BINDHU1, DR. KUDIPUDI HARINADHA BABA*
1Pharm.
D, Narayana Pharmacy College, Nellore, Andhra
Pradesh, India.
2Principal, Narayana Pharmacy College, Nellore, Andhra Pradesh, India.
Corresponding Author: Dr. Kudipudi Harinadha Baba, Pharm. D, Narayana Pharmacy College, Nellore, Andhra Pradesh, India, E-mail: harinadha_baba@yahoo.co.in
Citation: Irripothu Paula Preethi, Yetigadda Vamsi Priya, Sunkara Hima Bindhu, Dr.Kudipudi Harinadha Baba, (2021). Evaluation of Safety and Efficacy of Ticagrelor with other selected Anti-platelet agents in acute coronary syndrome at a Tertiary care hospital. Int Res J Clin Stud Pharm Trends, 1(2); 1-4.
Copyright: © 2021, Irripothu Paula Preethi, Yetigadda Vamsi Priya, Sunkara Hima Bindhu, Dr. Kudipudi Harinadha Baba (2021). This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International License, which permits unrestricted use, distribution and reproduction in any medium, provided the original author and source are credited.
ABSTRACT:
The study was designed to evaluate the efficacy and safety of Ticagrelor with other selected anti platelet agents in Acute coronary syndrome. A prospective study was done on 210 patients of both the sexes above 18 years of age in the Department of Cardiology at a tertiary care hospital in Nellore for a period of six months. The primary endpoint is the composite of death, myocardial infarction or stroke and the Safety endpoint is adverse effects of drugs. Statistical analysis was performed using Kruskal Wallis test in SPSS. A total of 210 patients of age 30 to 90 were randomised to Aspirin (n= 50), Clopidogrel (n=50), Ticagrelor (n=30), Prasugrel (n= 30), Aspirin+Clopidogrel (n = 50) in Acute coronary syndrome. After 3 months follow-up, statistically there is a significant difference (p=0.014) in safety endpoint of selected anti platelet drug groups and the efficacy end point did not differ statistically (p= 0.083). The incidence of primary composite endpoint was reduced with ticagrelor compared to aspirin, clopidogrel prasugrel and combination therapy. In ACS patients, the Safety and Efficacy treatment with Ticagrelor compared with other selected antiplatelet drugs shown depletion in major adverse Cardiovascular events without a significant increase in bleeding events.
KEYWORDS:
.png)
.jpg)
.gif)
.jpg)
